Mobile

An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androg...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-021434-55

An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

PSA level [ Time Frame: Every 3 months during 27 months of treatment ] [ Designated as safety issue: Yes ]

Critère d'inclusion

  • Prostate cancer

Liens